Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10665632 | 0.82 | LIPG (0.41) | CTSB | |
| SCHEMBL780568 | 0.81 | CTSB (0.55) | CTSBHSD11B1LOXL2GABRA1GABRB2 | |
| Water SCHEMBL29718461 | 0.80 | CTSB (0.50) | CTSBHSD11B1LOXL2GABRA1GABRB2 | |
| SCHEMBL10179924 | 0.79 | CTSB (0.53) | CTSBHSD11B1LOXL2GABRA1GABRB2 | |
| SCHEMBL2024322 | 0.79 | CTSB (0.53) | CTSBHSD11B1LOXL2GABRA1GABRB2 | |
| SCHEMBL330706 | 0.79 | CTSB (0.53) | CTSBHSD11B1LOXL2GABRA1GABRB2 | |
| SCHEMBL29764441 | 0.78 | CTSB (0.49) | CTSBHSD11B1LOXL2GABRA1GABRB2 | |
| SCHEMBL301742 | 0.77 | CA2 (0.52) | CTSBHSD11B1LOXL2 | |
| SCHEMBL30096522 | 0.77 | CA2 (0.52) | CTSBHSD11B1LOXL2 | |
| SCHEMBL4256900 | 0.77 | PLCG1 (0.54) | CTSBHSD11B1LOXL2GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | claimed |
| US-8440711-B2 | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2013-05-14 | — | — | US | claimed |
| EP-2094638-B1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-08-08 | — | — | EP | claimed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-03-25 | — | — | US | claimed |
| EP-2094638-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-09-02 | — | — | EP | claimed |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | DOMPE PHA.R.MA S.P.A. (IT) | 2009-08-13 | — | — | US | claimed |
| WO-2008075184-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2008-06-26 | — | — | WO | claimed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | claimed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | claimed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | claimed |
| US-10190009-B2 | Ink composition, ink jet recording method using same, and colored material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20160160065-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3015516-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | Nippon Kayaku Kabushiki Kaisha (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-9328057-B2 | Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004052830-A1 | CHIRAL ARYLKETONES IN THE TREATEMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DESEASES | DOMPE S.P.A. (IT) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | disclosed |
| US-6410749-B1 | REACTING A CARBONYL COMPOUND WITH ORGANOMETALLIC COMPOUND | NIPPON SODA CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1146037-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FPR2, FPR3, FPR1 | CTSB 393/4885HSD11B1 2412/4885LOXL2 1193/4885 |
| US-20090203652-A1 | CHIRAL ARYLKETONES IN THE TREATMENT OF NEUTROPHIL-DEPENDENT INFLAMMATORY DISEASES | NR1H4, MMP8, NR1I2 | CTSB 1155/4885HSD11B1 259/4885LOXL2 2746/4885 |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | CTSB 1945/4885HSD11B1 2901/4885LOXL2 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.